Kornimate/medical-research-clean huggingface dataset:
effect of betamethasone gel and lidocaine jelly on sore throat, cough and hoarseness of

Conditions: Sore Throat; Cough

Summary: abstract: the aim of this study was to investigate the effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence. this study has not been carried out in iran. 99 patients of either sex undergoing elective surgery were recruited in a single blind randomized study. the patients, using randomization table, were divided into three groups. anesthetics and medications used during surgery were similar for all the patients. for the all patients, the incidence of postoperative sore throat, cough and hoarseness of the voice in the different follow-up periods (1, 6 and 24 hours) based on the different types of medications were obtained.


Eligibility criteria:
inclusion criteria: 1. 50 years\ 15 years 2. no acute upper respiratory infections and no sore throat 3. candidate for elective surgery unrelated to the throat 4. the lack of airways difficulties 5. candidate for general anesthesia with intubation 6. no contraindications for receiving steroid 7. surgery time \< 240 minutes 8. intubation up to 2 times 9. tracheal tube cuff pressure = 25-30 cm h2o 10. fasting for 8-6 hours prior to surgery 11. asa i and asaii and 12. surgery under general anesthesia and endotracheal intubation exclusion criteria: 1. use of nasogastric tube or throat packs 2. patients with upper respiratory tract infection 3. patients on steroid therapy were excluded from the study

Keywords: syndrome incidence after intubation betamethasone gel lidocaine jelly sore throat cough hoarseness of voice
couples-based behavioral psychotherapy for male patients with posttraumatic stress disorder and alcohol dependence

Conditions: PTSD; Alcohol Dependence

Summary: purpose: phase i focus groups with clinicians and patients will gather qualitative data to focus and inform the content of phase ii. in phase ii, 12 weeks of psychotherapy will be offered to evaluate feasibility and potential efficacy of a couples-based, integrated treatment for men with ptsd and alcohol dependence. hypotheses: we predict that this experimental psychotherapy, partners encouraging abstinence and coping with emotions (peace), will reduce patient drinking, reduce ptsd symptoms, and improve relationship functioning.


Eligibility criteria:
inclusion criteria: * male patients * one to six weeks of abstinence from alcohol and other drugs * both partners agree to stated goals of abstinence from alcohol and drugs, reduction of ptsd symptoms, and relationship improvement * current diagnoses of both alcohol dependence and ptsd * receiving treatment for one or both disorders * functionally able to participate in outpatient treatment as determined by p.i. "functionally able" includes access to transportation. * alcohol is "drug of choice" (history of other drugs acceptable) * married or cohabiting in stable relationship for at least 6 months. separated couples may participate if attempting to reconcile * patient willing to sign release of information allowing researchers to communicate with patient's clinician regarding treatment goals exclusion criteria: * spouse or partner also has an alcohol or drug problem as determined by p.i. based on report by patient or partner or as revealed on alcohol use disorders identification test (audit) or the drug abuse screening test (dast) given to partner at intake assessment * mental retardation or learning disorder by clinician report or patient chart * psychotic disorder as determined by patient's chart or scid * patient currently receiving methadone or another opiate agonist by patient report or chart * current fear of partner or history of severe domestic violence in the past year. an example of severe violence would be a couple reporting an episode of violence that required medical attention. such couples will be excluded from the study and referred to domestic violence treatment. couples who have experienced mild to moderate domestic violence may participate in phase ii of the study.

Keywords: ptsd alcohol dependence
outpatient administration of r-dhap in relapsed/refractory non-hodgkin lymphoma

Conditions: Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma

Summary: the goal of this study is to evaluate the efficacy and safety of a combination of the anti-cd20 monoclonal antibody rituximab, dexamethasone, daily high dose cytarabine twice, and carboplatin; delivered in an outpatient setting.

the r-dhap (rituximab, dexamethasone, cytarabine, and cisplatin) schedule includes high-dose cytarabine every 12 hours and requires careful monitoring of renal toxicity because of cisplatin. these conditions limit the use of this protocol in an outpatient setting. the s phase of lymphoma cells is longer than 12 hours, then cytarabine can be used daily without reduction of the antineoplastic effect. carboplatin does not have remarkable renal toxicity so is not necessary to monitor blood chemistry or iv fluids during its administration. the study hypothesis is that modifications to the original r-dhap protocol, using cytarabine on a daily basis and the substitution of cisplatin by carboplatin can preserve the efficacy, reducing the incidence of renal events. the investigators hypothesize that those modifications can make the schedule more suitable for an outpatient administration in relapsed or refractory non-hodgkin lymphoma patients. after 3 cycles of chemotherapy, the overall response and the incidence of adverse events will be evaluated. in order to achieve the purpose of this trial, 130 participants will be included.

Eligibility criteria:
inclusion criteria: * diagnosis of recurrent or refractory b-cell non-hodgkin lymphoma * performance status: eastern cooperative oncology group 0-2 * at least three weeks from last chemotherapy * toxicities by common terminology criteria version 4.0 ≤ 1 * glomerular filtration rate \>50 ml/min * women of childbearing potential must use effective methods of contraception exclusion criteria: * post-transplant relapse of lymphoma * central nervous system involvement of lymphoma * serious infections * known allergies to one or more of the experimental drugs * diabetes with glucose \>200 mg/dl * pregnant or lactating females * known hiv or b hepatitis positivity * known allergies to filgrastim
german pms trial (awb) to evaluate therapy in reflux disease and nsar-symptoms

Conditions: Gastroesophageal Reflux

Summary: this pms study had the objective to evaluate under ordinary medical care conditions the efficacy and tolerability of esomeprazole in patients who where treated by general practitioners and internists.


Eligibility criteria:
inclusion criteria: * patients with gerd, or nsaid related ulcers, who need treatment with esomeprazole. exclusion criteria: * limitations; possible risks; warnings; contraindications mentioned in the spc.

Keywords: reflux nsar treatment patients with reflux symptoms or gastrointestinal symptoms after nsar treatment
neuronavigated tbs in depression

Conditions: Depression

Summary: in this randomized controlled trial we will treat 80 patients with depression with intermittent theta burst stimulation in two parallel arms. both arms are active interventions differing with respect to positioning of the treatment coil - one arm with neuronavigation and one arm with targeting according to eeg position representing the left dorsolateral prefrontal cortex. randomisation will be balanced for in- and out-patients and for the treatment arms.

intermittent theta burst stimulation (itbs) is a specific type of repetitive transcranial magnetic stimulation (rtms). rtms of the left prefrontal cortex was shown to be effective in the treatment of depression. recent studies showed that itbs probably is as effective as rtms. one possibility to increase to efficacy of rtms/itbs is to use neuronavigation. with neuronavigation the coil position can be targeted with an accuracy in the range of millimeters. furthermore the stimulation position can be ensured during one single session and over the course of the daily treatments. the aim of the present study is to investigate the benefit of neuronavigation in the treatment of depression with itbs by using two arms one with targeting the stimulation site with neuronavigation and one by using the eeg position f3 as target by using head caps for marking the position.

Eligibility criteria:
inclusion criteria: * unipolar or bipoloar depressive episode according to icd-10 * at least moderate depression according to hamilton depression rating scale or icd-10 * if applicable stable medication with psychoactive compounds for out-patients * if applicable no or stable treatment for depression during the course of the trial * residence in germany and mother tongue german * written informed consent exclusion criteria: * meeting the contraindications for transcranial magnetic stimulation or magnetic resonance imaging (electic devices or metal implants in the body, e.g. cardiac pace maker, insulin ppump) * neurological disorders (e.g. cerebrovascular events, neurodegenerative disorder, epilepsy, brain malformation, severe head trauma) * addictive disorder with consumption in the last two years * regular intake of benzodiazepines * participation in another study parallel to the trial * pregnancy or breastfeading period * psychiatric confinement
pilot study with the aim to quantify a stress protein in the blood and in the urine for the monitoring and early diagnosis of malignant solid tumors

Conditions: Cancer

Summary: recent studies shows that extracellular vesicles (named "exosomes") released by cancer cells exhibit at their membrane the stress protein hsp70, contrary to exosomes released by normal cells. these exosomes ("hsp70-exosomes") have a very important role in intercellular communication and have specific biological functions that can promote tumor progression. they are found in the different biological fluids such as blood and urine. we have developed a protocol able to isolate exosomes in blood and urine. we also demonstrated that only exosomes derived from cancer cell have hsp70 at their membrane. those results strongly suggest that we can only identify exosomes with hsp70 at the membrane in patients with cancer. detection of hsp70-exosomes in the diagnosis of patients is a promising pathway of research. because a cancer cell can releases a large amount of exosomes (several billion) and since its appearance, our approach will allow to earlier detect cancer with respect to the use of imaging and circulating tumor cells (ctcs), which remains a rare event (about one ctc of 1 billion cells). the aim of this study is to demonstrate that hsp70-exosomes could be used for early diagnosis of patients with malignant solid tumor. in order to demonstrate this, the objective of the study is to study blood and urine samples from 60 subjects with a malignant tumor and 20 healthy subjects (witness).


Eligibility criteria:
inclusion criteria for patients * women newly diagnosed with either: * infiltrating non-metastatic breast cancer (positive or negative her2 status or hormone therapy) * breast cancer with a first metastasis evolution (positive or negative her2 status or hormone therapy). * ovarian cancer stage iii and iv, * men and women who are newly diagnosed non-small cell lung cancer metastatic, * age ≥18 years * affiliation to a social security system, * signed informed consent. exclusion criteria for patients: * patient with another synchronous tumor, * men with breast cancer, * positive hiv and / or hbv and / or hcv serology * patients unable to undergo a medical monitoring for geographical, social or psychological condition, * pregnant or nursing women, * people enjoying a major protection system (including trusteeship and guardianship). inclusion criteria for healthy volonter * men or women aged 50-70 years (mean age of onset of various cancers in the study) * affiliation to a social security system, * signed informed consent. exclusion criteria for healthy volonter * history of cancer, * positive hiv and / or hbv and / or hcv serology * pregnant or nursing women, * people enjoying a major protection system (including trusteeship and guardianship).

Keywords: personalized care early diagnosis ovarian cancer breast cancer lung cancer early detection cancer [e01.390.500]
a study to test how insulin nnc0471-0119 h works in the body in participants with type 1 diabetes when given by an insulin pump

Conditions: Diabetes Mellitus, Type 1

Summary: the study is looking at the effect and safety of a new fast-acting insulin (nnc0471 0119) to people with type 1 diabetes when given by an insulin pump. the study tests how fast insulin nnc0471-0119 enters your bloodstream, how long it stays there and how much it lowers blood sugar. the new insulin nnc0471-0119 will be compared to insulin aspart. the participants will get each study medicine administered at separate clinic visits. the study will last for about 1-3 months.


Eligibility criteria:
inclusion criteria: * male or female aged 18-64 years (both inclusive) at the time of signing the informed consent. * diagnosed with type 1 diabetes (t1d) greater than or equal to (≥) 1 year before screening. * insulin administration using continuous subcutaneous insulin infusion via a pump greater than or equal to (≥) 90 days before screening. * current daily insulin treatment between 0.2 and 1.2 insulin units per kilogram per day \[(i)u/kg/day\] (both inclusive). exclusion criteria: * known or suspected hypersensitivity to study intervention(s) or related products. * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods.
influence of residual astigmatism on visual acuity in patients undergoing cataract surgery with trifocal intraocular lens implantation

Conditions: Cataract After; Astigmatism; IOL; Visual Acuity

Summary: main objective: to assess the influence of residual astigmatism on visual acuity in the different lens foci in patients operated on for cataracts with a trifocal intraocular lens implant. secondary objective: to study the influence of residual astigmatism on the visual quality of the patient in the far focus and to determine if there are differences of affectation in the two study groups.

it will be studied how small residual astigmatisms after cataract surgery degrade the visual acuity of patients in the three focal planes of trifocal iols. not only va will be studied, but also visual quality through contrast sensitivity curves.

Eligibility criteria:
inclusion criteria: * bilateral surgery performed by the same surgeon * iols implanted iols finevision (microf) and finevision toric (podft) * patients with pre-surgery corneal astigmatism less than 2.5 d * patients whose pupillary diameter in physiological position (conditions of lower photopic pupil) not over 4 mm. exclusion criteria: * post-surgical refractive residual astigmatisms ≧ 1.55d * previous corneal or intraocular surgeries * active diseases * eye complications during the 3-month follow-up

Keywords: csf contrast sensitivity trifocal iol
an evaluation of the onset and duration of action of akf-1 ophthalmic solution in treating acute allergic conjunctivitis

Conditions: Allergic Conjunctivitis

Summary: the purpose of this study is to evaluate the onset and duration of action of two concentrations of akf-1 ophthalmic solution compared to vehicle in the conjunctival allergen challenge (cac) model of acute allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * positive bilateral conjunctival allergen challenge (cac) reaction exclusion criteria: * known contraindications or sensitivities to the study medication or its components * any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters * use of disallowed medication during the period indicated prior to the enrollment or during the study
safety and efficacy study of healos as a bone replacement to treat degenerative disc disease

Conditions: Degenerative Disc Disease

Summary: the purpose of this study is to determine the safety and effectiveness of healos compared with autograft using the transforaminal lumbar interbody fusion (tlif) method.


Eligibility criteria:
inclusion criteria: * persistent back and/or leg pain refractory to 6 months of non-surgical therapy * male or female 18 to 70 years of age (inclusive) * objective evidence of significant disc degeneration at one or two adjacent lumbar level(s) from l2/l3 to l5/s1 exclusion criteria: * significant disc degeneration at more than two adjacent levels * greater than grade ii spondylolisthesis * prior fusion surgery of the lumbar spine (prior discectomies and intradiscal electrothermal therapy \[idet\] are allowed) * insulin-dependent diabetes mellitus * pregnant or lactating, or wishes to become pregnant within the 24 month duration of the study

Keywords: one or two level degenerative disc disease
the efficacy of preseasonal omalizumab treatment

Conditions: Seasonal Allergic Rhinitis

Summary: allergic rhinitis (ar) is induced by an immunoglobulin e (ige)-mediated reaction in the allergen-sensitized subjects, affecting 10% to 40% of the world population. ar could be divided into two kinds, perennial ar and seasonal ar (sar). in recent years, biologics have become promising drugs for allergic diseases. the efficacy and safety of omalizumab in treating sar have been well proven by previous studies. however, the efficacy in preseasonal treatment for sar has not yet been studied before.


Eligibility criteria:
inclusion criteria: * male or female outpatients aged 18 to 60 years (inclusive). * with history of sar for at least two years, with/without conjunctivitis and without asthma * two or more nasal symptoms scores were ≥ 2 points during july - october in the last year. * sensitised to common autumn pollens including sagewort and ragweed (a specific ige level ≥ 3.5 ku/l). * patients who have been informed of the nature and aims of the study and have given their written consent, willing to comply with the protocol. * patients who are able to understand the information given and the consent and complete the daily record card. exclusion criteria: * patients with oral diseases/ allergies within the run-in period. * patients accepted any kind of operations within 4 weeks of the run-in period. * patients applied for systemic glucocorticoids within 4 weeks in the run-in period. * patients with par. * patients with any nasal condition that could confound the results of the study (chronic rhinitis, chronic rhinosinusitis with/without polyps). * whatever the co-sensitization leading to clinically relevant ar, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study. * patients with comorbidity of severe asthma. * patients applying beta-antagonist (local or systemic appliance). * pregnant, breast-feeding / sexually active women of childbearing potential. * patients treated with ait for pollens within 3 years. * participation in any clinical study within the 3 months of the run-in period. * patients at risk of non-compliance.. * patients with immunologic suppression, diabetes mellitus, autonomic neuropathy, coronary heart disease or hypertension.
the norwegian immunotherapy in multiple myeloma study

Conditions: Myeloma Multiple; Plasma Cell Leukemia; AL Amyloidosis

Summary: the goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in norway. the aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.


Eligibility criteria:
inclusion criteria * participants age ≥ 18 years * prior diagnosis of one of the following * multiple myeloma as defined according to imwg criteria * primary plasma cell leukemia as defined according to imwg consensus definition * al-amyloidosis as defined according to imwg criteria * planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the eu): * teclistamab (tecvayli) * elranatamab (elrexfio) * talquetamab (talvey) * idecabtagene vicleucel (ide-cel/abecma) * ciltacabtagene autoleucel (cilta-cel/carvykti) exclusion criteria: * none

Keywords: bispesific antibodies teclistamab elranatamab talquetamab cilta-cel ide-cel ciltacabtagene autoleucel idecabtagene vicleucel crs ican infections supportive care
a trial comparing routine versus selective use of completion angiography after surgical thromboembolectomy in the treatment of acute lower limb ischemia and their impacts on limb salvage rates

Conditions: Acute Limb Ischemia

Summary: this randomized controlled trial will compare the impact of routine use of completion angiography versus using it on selective bases after thromboembolectomy in patients with acute lower limb ischemia and their impact on limb salvage rates


Eligibility criteria:
inclusion criteria: * grade i (1) (viable) acute ischemia which there is no immediate threat of limb loss; the patient is presented with neither sensory nor motor weakness and there are audible doppler signals in both arteries and veins. * grade iia (2 a) (marginally threatened) acute ischemia which needs proper treatment to save the limb; the patient is presented with a minimal sensory loss, no motor weakness, inaudible arterial doppler signals but the venous doppler signals are still audible. * grade iib (2 b) (immediately threatened) acute ischemia which needs immediate revascularization to save the limb; the patient is presented with a sensory loss associated with rest pain, mild to moderate motor weakness, inaudible arterial doppler signals but the venous doppler signals are still audible. exclusion criteria: * traumatic or iatrogenic acute limb ischemia * grade iii acute ischemia (irreversible) with major tissue loss and major amputation is inevitable; the patient presented with sensory and motor loss, inaudible arterial and venous doppler signals. * patients with occluded bypass graft. * acute limb ischemia due to intra-arterial injection * patients with chronic renal impairment (serum creatinine \> 1.2) or with a history of contrast-induced nephropathy. * acute lower limb ischemia due to thrombosed aneurysms

Keywords: limb ischemia completion angiography thromboembolectomy
how brazilian chiropractors are facing the covid-19 pandemic

Conditions: Covid19

Summary: brazil has the latin america's largest coronavirus outbreak, numbers second only to the united states in the western hemisphere. the first covid-19 confirmed case in brazil was on february of 2020. a 61yrs old man tested positive after returning from a trip to italy. few other very first cases were also imported from europe by returning travelers. the first locally transmitted case was registered on march of 2020, when a total of 8 cases have already been confirmed. at the time the who declares the outbreak as a pandemic (march 11) brazil had 52 confirmed cases being 6 of those locally transmitted. healthcare professionals are now more important than ever. given the intrinsic nature of the hands-on treatment of the chiropractic profession, it is extremely important to understand what strategies chiropractors have put in place to address patient care, safety, and self report covid contamination of those professionals.


Eligibility criteria:
inclusion criteria: * chiropractors graduated from national or international accredited colleges. exclusion criteria: * chiropractors who did not treated patients in 2020.

Keywords: chiropractors strategies coronavirus pandemic